Ultragenyx Pharmaceutical Inc. reaffirmed earnings guidance for the year 2024. For the full year 2024, the company reaffirms: Total revenue in the range of $500 million to $530 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.87 USD | -1.74% | +1.58% | -12.44% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.44% | 3.54B | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024